ALX Oncology Announces Participation at Upcoming Investor Conferences
08 Settembre 2020 - 1:00PM
ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a
clinical-stage immuno-oncology company developing therapies that
block the CD47 checkpoint pathway, today announced that Jaume Pons,
Ph.D., President and Chief Executive Officer and other senior
executives, will participate in two upcoming virtual investor
conferences in September:
Cantor Virtual Healthcare
Conference Format: Fireside chat with Alethia Young,
Director of ResearchDate: Tuesday, September 15, 2020Time: 1:20 PM
Eastern TimeWebcast link: Available here
H.C. Wainwright 22nd Annual Global
Investment ConferenceFormat: Corporate Presentation Date:
Wednesday, September 16, 2020Time: 2:30 PM Eastern TimeWebcast
link: Available here
Company management will also be participating in
one-on-one investor meetings at both conferences.
A live webcast of the events can also be
accessed by visiting the Investors section of ALX Oncology’s
website at www.alxoncology.com and selecting the Investor Calendar
under the “News & Events” tab. A replay of the webcasts will be
archived for up to 90 days following the presentation dates.
About ALX Oncology
ALX Oncology is a clinical-stage immuno-oncology
company focused on helping patients fight cancer by developing
therapies that block the CD47 checkpoint pathway and bridge the
innate and adaptive immune system. ALX Oncology’s lead product
candidate, ALX148, is a next generation CD47 blocking therapeutic
that combines a high-affinity CD47 binding domain with an
inactivated, proprietary Fc domain. ALX148 has demonstrated
promising clinical responses across a range of hematologic and
solid malignancies in combination with a number of leading
anti-cancer agents. ALX Oncology intends to advance ALX148 into
clinical development for the treatment of myelodysplastic syndromes
and to continue clinical development for the treatment of a range
of solid tumor indications.
Investor Contact:
Peter Garcia
Chief Financial Officer, ALX Oncology
(650) 466-7125 Ext. 113
peter@alxoncology.com
Argot Partners
(212)-600-1902
alxoncology@argotpartners.com
Media Contact:
Karen Sharma
MacDougall
(781) 235-3060
alx@macbiocom.com
Grafico Azioni ALX Oncology (NASDAQ:ALXO)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni ALX Oncology (NASDAQ:ALXO)
Storico
Da Lug 2023 a Lug 2024